Genmab — Februar 2020
-
Merck ejer pembro
-
Recruitment Status : Withdrawn (Business Reasons) https://clinicaltrials.gov/ct2/show/NCT03221634
-
Nu vi snakker om BMS: "Den amerikanske medicinalkoncern Bristol-Myers Squibb, der for nyligt har gennemført det 74 mia. dollar store opkøb af biotekselskabet Celgene, har torsdag aflagt regnskab for fjerde kvartal, hvor indtjeningen overrasker positivt, mens prognoserne for 2020 er lidt til den svage side.
Aktien indikeres dog 3,0 pct. højere i det amerikanske formarked." -
Controversy in the Use of CD38 Antibody for Treatment of Myeloma: Is High CD38 Expression Good or Bad? https://www.mdpi.com/2073-4409/9/2/378
-
-
part of Special Issue "CD38 and Disease: A Bi-Directional Cross-Talk between Pathology and Physiology" https://www.mdpi.com/journal/cells/special_issues/CD38_CD157
-
this part has focus on CD38 in Solid Tumors https://www.mdpi.com/2073-4409/9/1/52/htm
-
Tisotumab Vedotin Program Highlights
Tisotumab Vedotin innovaTV 204 Pivotal Trial Data Expected in 2020: Seattle Genetics and Genmab expect to report topline data in the first half of 2020 from the innovaTV 204 pivotal trial of tisotumab vedotin in patients with recurrent and/or metastatic cervical cancer who have relapsed or progressed after standard-of-care treatment.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind